On Friday, Shares of TECO Energy, Inc. (NYSE:TE), climbed 1.74%, to $ 18.10.
Peoples Gas, Florida’s largest natural gas distribution utility with more than 350,000 customers, led the country’s utilities in brand trust according to a recent trusted brand and customer engagement survey conducted by Cogent Reports, a division of Market Strategies International. “We are proud to be recognized by our customers as a trusted brand,” said Bruce Narzissenfeld, vice president of Customer Service. “We work hard to deliver reliable and affordable energy with a strong focus on customer service that exceeds customer expectations.”
The web-based survey looked at 125 electric, natural gas and combination utilities across the country. More than 25,000 residential utility customers responded.
TECO Energy, Inc., an electric and gas utility holding company, engages in the regulated electric and gas utility operations. It generates, purchases, transmits, distributes, and sells electric energy to retail customers, in addition to to utilities and other resellers of electricity in West Central Florida; and has electric generating plants with a winter peak generating capacity of 4,668 megawatts.
Shares of Bioline RX Ltd (NASDAQ:BLRX), dipped -5.66% to $ 2.50.
Bioline RX Ltd, declared that it will present positive safety results of its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease, at the 16th International Celiac Disease Symposium (ICDS 2015), to take place from June 21-24 in Prague, Czech Republic. The Phase 1/2 results were formerly declared in November 2014.
Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential Treatment of Celiac Disease - a Phase 1/2 Safety Study in Celiac Patients, on Wednesday, June 24, in the Novel Treatments session. BL-7010 was found to be safe and well tolerated in the single-dose phase, and the optimal safe dose for future development was determined in the repeated-dose phase. The Company is in the final stages of additional non-clinical studies and formulation development for BL-7010 in preparation for the forthcoming randomized, placebo-controlled efficacy study, which is predictable to commence in the fourth quarter of 2015.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.
Shares of Hanesbrands Inc. (NYSE:HBI), during its Friday’s trading session fell -0.15%, to $33.96.
Hanesbrands Inc., declared that it will present positive safety results of its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease, at the 16th International Celiac Disease Symposium (ICDS 2015), to take place from June 21-24 in Prague, Czech Republic. The Phase 1/2 results were formerly declared in November 2014.
Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential Treatment of Celiac Disease - a Phase 1/2 Safety Study in Celiac Patients, on Wednesday, June 24, in the Novel Treatments session. BL-7010 was found to be safe and well tolerated in the single-dose phase, and the optimal safe dose for future development was determined in the repeated-dose phase. The Company is in the final stages of additional non-clinical studies and formulation development for BL-7010 in preparation for the forthcoming randomized, placebo-controlled efficacy study, which is predictable to commence in the fourth quarter of 2015.
Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells a range of basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International.
Finally, Albemarle Corporation (NYSE:ALB) , gained 1.05% $ 55.03.
Albemarle Corporation, declared that it will release its second quarter 2015 earnings after the NYSE closes on Wednesday, August 5, 2015.
The company will hold its conference call to talk about second quarter 2015 results on Thursday, August 6, 2015 at 9:00 am ET. This call is being webcast by NASDAQ OMX and can be accessed at Albemarle Corporation’s website at http://investors.albemarle.com or by phone at the following number:
Dial-In #: 888-680-0869
International Dial-In #: 617-213-4854
Participant Passcode: 45458728
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. The company’s Performance Chemicals segment offers brominated flame retardants under the Saytex brand; mineral-based flame retardants under the Martinal and Magnifin brands; and elemental bromine, alkyl bromides, inorganic bromides, brominated powdered activated carbon, and bromine fine chemicals that are used in chemical synthesis, oil and gas well drilling and completion fluids, mercury control, paper manufacturing, water purification, beef and poultry processing, and various other industrial applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
